WEKO3
アイテム
{"_buckets": {"deposit": "5c7c9958-aa42-4a06-bf50-a8e7e158645c"}, "_deposit": {"created_by": 3, "id": "19770", "owners": [3], "pid": {"revision_id": 0, "type": "depid", "value": "19770"}, "status": "published"}, "_oai": {"id": "oai:kindai.repo.nii.ac.jp:00019770", "sets": ["4459"]}, "author_link": ["33623"], "item_8_biblio_info_21": {"attribute_name": "書誌情報", "attribute_value_mlt": [{"bibliographicIssueDates": {"bibliographicIssueDate": "2018", "bibliographicIssueDateType": "Issued"}, "bibliographicPageEnd": "4", "bibliographicPageStart": "1", "bibliographic_titles": [{"bibliographic_title": "科学研究費助成事業研究成果報告書 (2017)"}]}]}, "item_8_date_19": {"attribute_name": "日付 作成日", "attribute_value_mlt": [{"subitem_date_issued_datetime": "2018-11-20", "subitem_date_issued_type": "Created"}]}, "item_8_description_33": {"attribute_name": "抄録", "attribute_value_mlt": [{"subitem_description": "研究成果の概要(和文):EGFR-TKIに耐性を示した後にニボルマブを使用したEGFR変異陽性非小細胞肺がん25例(T790M変異陽性8例)の有効性および免疫関連因子を検討した。陰性症例は陽性と比較して良好な有効性及び、PD-L1が高発現の傾向を示した。ニボルマブ使用症例9例の全エクソーム解析にてnon-synonymous mutation数を評価したところ、奏効例では有意にmutation数が高値であった。EGFR-TKI耐性症例に関しての耐性機序毎の抗PD-1抗体の有効性やnon-synonymous mutationを評価した初の報告であり、Annals of Oncology誌にて報告した。\n研究成果の概要(英文):The efficacy of PD-1 blockade in EGFR mutated NSCLC with different mechanisms of acquired resistance to EGFR-TKIs is unknown. We retrospectively evaluated nivolumab efficacy and immune-related factors in such patients according to their status for the T790M resistance mutation of EGFR.We identified 25 patients with EGFR mutation-positive NSCLC who were treated with nivolumab. Whole-exome sequencing of tumor DNA was carried out to identify gene alterations. Efficacy of nivolumab tended to increase as the PD-L1 expression level increased with cutoff values of 10% and 50%.The proportion of tumors with a PD-L1 level of10% or50% was higher among T790M-negative patients than among -positive patients. Nivolumab responders had a significantly higher CD8+ TIL density and nonsynonymous mutation burden. T790M-negative patients with EGFR mutation-positive NSCLC are more likely to benefit from nivolumab after EGFR-TKI treatment, possibly as a result of a higher PD-L1 expression level.", "subitem_description_type": "Abstract"}]}, "item_8_description_36": {"attribute_name": "内容記述", "attribute_value_mlt": [{"subitem_description": "研究種目:若手研究(B); 研究期間:2016~2017; 課題番号:16K21506; 研究分野:臨床腫瘍学; 科研費の分科・細目:", "subitem_description_type": "Other"}]}, "item_8_description_37": {"attribute_name": "資源タイプ", "attribute_value_mlt": [{"subitem_description": "Research Paper", "subitem_description_type": "Other"}]}, "item_8_description_41": {"attribute_name": "フォーマット", "attribute_value_mlt": [{"subitem_description": "application/pdf", "subitem_description_type": "Other"}]}, "item_8_publisher_14": {"attribute_name": "出版者 名前", "attribute_value_mlt": [{"subitem_publisher": "近畿大学"}]}, "item_8_relation_11": {"attribute_name": "著者 外部リンク", "attribute_value_mlt": [{"subitem_relation_name": [{"subitem_relation_name_text": "https://kaken.nii.ac.jp/grant/KAKENHI-PROJECT-16K21506/"}]}]}, "item_8_text_10": {"attribute_name": "著者 役割", "attribute_value_mlt": [{"subitem_text_value": "研究代表者"}]}, "item_8_text_15": {"attribute_name": "出版社 カナ", "attribute_value_mlt": [{"subitem_text_value": "キンキダイガク"}]}, "item_8_text_16": {"attribute_name": "出版社 ローマ字", "attribute_value_mlt": [{"subitem_text_value": "Kinki Daigaku"}]}, "item_8_text_17": {"attribute_name": "出版年(from)", "attribute_value_mlt": [{"subitem_text_value": "2018"}]}, "item_8_text_53": {"attribute_name": "登録者(XooNIps)", "attribute_value_mlt": [{"subitem_text_value": "近畿大学中央図書館"}]}, "item_8_text_7": {"attribute_name": "著者(英)", "attribute_value_mlt": [{"subitem_text_language": "en", "subitem_text_value": "HAYASHI, Hidetoshi"}]}, "item_8_text_8": {"attribute_name": "著者 所属", "attribute_value_mlt": [{"subitem_text_value": "近畿大学医学部; 講師"}]}, "item_8_text_9": {"attribute_name": "著者所属(翻訳)", "attribute_value_mlt": [{"subitem_text_value": "Kindai University"}]}, "item_8_version_type_12": {"attribute_name": "版", "attribute_value_mlt": [{"subitem_version_resource": "http://purl.org/coar/version/c_be7fb7dd8ff6fe43", "subitem_version_type": "NA"}]}, "item_creator": {"attribute_name": "著者", "attribute_type": "creator", "attribute_value_mlt": [{"creatorNames": [{"creatorName": "林, 秀敏"}, {"creatorName": "ハヤシ, ヒデトシ", "creatorNameLang": "ja-Kana"}], "nameIdentifiers": [{"nameIdentifier": "33623", "nameIdentifierScheme": "WEKO"}, {"nameIdentifier": "10548621", "nameIdentifierScheme": "研究者番号", "nameIdentifierURI": " "}]}]}, "item_files": {"attribute_name": "ファイル情報", "attribute_type": "file", "attribute_value_mlt": [{"accessrole": "open_date", "date": [{"dateType": "Available", "dateValue": "2018-11-20"}], "displaytype": "detail", "download_preview_message": "", "file_order": 0, "filename": "16K21506seika.pdf", "filesize": [{"value": "197.3 kB"}], "format": "application/pdf", "future_date_message": "", "is_thumbnail": false, "licensetype": "license_free", "mimetype": "application/pdf", "size": 197300.0, "url": {"label": "16K21506seika.pdf", "url": "https://kindai.repo.nii.ac.jp/record/19770/files/16K21506seika.pdf"}, "version_id": "860a4379-054e-4b25-8ce8-91325670b06c"}]}, "item_keyword": {"attribute_name": "キーワード", "attribute_value_mlt": [{"subitem_subject": "バイオマーカー", "subitem_subject_scheme": "Other"}, {"subitem_subject": "個別化医療", "subitem_subject_scheme": "Other"}, {"subitem_subject": "免疫チェックポイント阻害薬", "subitem_subject_scheme": "Other"}]}, "item_language": {"attribute_name": "言語", "attribute_value_mlt": [{"subitem_language": "jpn"}]}, "item_resource_type": {"attribute_name": "資源タイプ", "attribute_value_mlt": [{"resourcetype": "research report", "resourceuri": "http://purl.org/coar/resource_type/c_18ws"}]}, "item_title": "driver遺伝子異常肺癌に対する分子標的薬の耐性化と、抗PD1抗体の有効性", "item_titles": {"attribute_name": "タイトル", "attribute_value_mlt": [{"subitem_title": "driver遺伝子異常肺癌に対する分子標的薬の耐性化と、抗PD1抗体の有効性"}, {"subitem_title": "Resistance mechanis of molecular targeted therapy and tumor micro environment as the immune-checkpoint inhibitor\u0027s biomarker", "subitem_title_language": "en"}]}, "item_type_id": "8", "owner": "3", "path": ["4459"], "permalink_uri": "https://kindai.repo.nii.ac.jp/records/19770", "pubdate": {"attribute_name": "公開日", "attribute_value": "2018-11-20"}, "publish_date": "2018-11-20", "publish_status": "0", "recid": "19770", "relation": {}, "relation_version_is_last": true, "title": ["driver遺伝子異常肺癌に対する分子標的薬の耐性化と、抗PD1抗体の有効性"], "weko_shared_id": 3}
driver遺伝子異常肺癌に対する分子標的薬の耐性化と、抗PD1抗体の有効性
https://kindai.repo.nii.ac.jp/records/19770
https://kindai.repo.nii.ac.jp/records/197706df8370b-b43d-46ae-9283-2f3f7d9cac0e
名前 / ファイル | ライセンス | アクション |
---|---|---|
16K21506seika.pdf (197.3 kB)
|
|
Item type | 研究報告書 / Research Paper(1) | |||||
---|---|---|---|---|---|---|
公開日 | 2018-11-20 | |||||
タイトル | ||||||
タイトル | driver遺伝子異常肺癌に対する分子標的薬の耐性化と、抗PD1抗体の有効性 | |||||
タイトル | ||||||
言語 | en | |||||
タイトル | Resistance mechanis of molecular targeted therapy and tumor micro environment as the immune-checkpoint inhibitor's biomarker | |||||
著者 |
林, 秀敏
× 林, 秀敏 |
|||||
言語 | ||||||
言語 | jpn | |||||
キーワード | ||||||
主題 | バイオマーカー, 個別化医療, 免疫チェックポイント阻害薬 | |||||
資源タイプ | ||||||
資源タイプ識別子 | http://purl.org/coar/resource_type/c_18ws | |||||
資源タイプ | research report | |||||
著者(英) | ||||||
en | ||||||
HAYASHI, Hidetoshi | ||||||
著者 所属 | ||||||
近畿大学医学部; 講師 | ||||||
著者所属(翻訳) | ||||||
Kindai University | ||||||
著者 役割 | ||||||
研究代表者 | ||||||
著者 外部リンク | ||||||
関連名称 | https://kaken.nii.ac.jp/grant/KAKENHI-PROJECT-16K21506/ | |||||
版 | ||||||
出版タイプ | NA | |||||
出版タイプResource | http://purl.org/coar/version/c_be7fb7dd8ff6fe43 | |||||
出版者 名前 | ||||||
出版者 | 近畿大学 | |||||
書誌情報 |
科学研究費助成事業研究成果報告書 (2017) p. 1-4, 発行日 2018 |
|||||
抄録 | ||||||
内容記述タイプ | Abstract | |||||
内容記述 | 研究成果の概要(和文):EGFR-TKIに耐性を示した後にニボルマブを使用したEGFR変異陽性非小細胞肺がん25例(T790M変異陽性8例)の有効性および免疫関連因子を検討した。陰性症例は陽性と比較して良好な有効性及び、PD-L1が高発現の傾向を示した。ニボルマブ使用症例9例の全エクソーム解析にてnon-synonymous mutation数を評価したところ、奏効例では有意にmutation数が高値であった。EGFR-TKI耐性症例に関しての耐性機序毎の抗PD-1抗体の有効性やnon-synonymous mutationを評価した初の報告であり、Annals of Oncology誌にて報告した。 研究成果の概要(英文):The efficacy of PD-1 blockade in EGFR mutated NSCLC with different mechanisms of acquired resistance to EGFR-TKIs is unknown. We retrospectively evaluated nivolumab efficacy and immune-related factors in such patients according to their status for the T790M resistance mutation of EGFR.We identified 25 patients with EGFR mutation-positive NSCLC who were treated with nivolumab. Whole-exome sequencing of tumor DNA was carried out to identify gene alterations. Efficacy of nivolumab tended to increase as the PD-L1 expression level increased with cutoff values of 10% and 50%.The proportion of tumors with a PD-L1 level of10% or50% was higher among T790M-negative patients than among -positive patients. Nivolumab responders had a significantly higher CD8+ TIL density and nonsynonymous mutation burden. T790M-negative patients with EGFR mutation-positive NSCLC are more likely to benefit from nivolumab after EGFR-TKI treatment, possibly as a result of a higher PD-L1 expression level. |
|||||
内容記述 | ||||||
内容記述タイプ | Other | |||||
内容記述 | 研究種目:若手研究(B); 研究期間:2016~2017; 課題番号:16K21506; 研究分野:臨床腫瘍学; 科研費の分科・細目: | |||||
資源タイプ | ||||||
内容記述タイプ | Other | |||||
内容記述 | Research Paper | |||||
フォーマット | ||||||
内容記述タイプ | Other | |||||
内容記述 | application/pdf |